The Paclitaxel Drug-Coated Device Controversy: Case Closed?

article image

New data presented at this year’s virtual TCT conference could help put to rest safety fears around the use of paclitaxel coated devices in the peripheral vasculature. That’s good news for medtech companies eager for a market recovery.

Study data presented at this year’s virtual Transcatheter Cardiovascular Therapeutics (TCT) meeting, held in mid-October, strongly suggest that safety fears over the use of paclitaxel drug-coated balloons and stents in the periphery should be put to rest, according to several physicians who spoke during the conference.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: